EGFR Ex20ins mutations account for around 12% of all EGFR mutations. These patients have historically faced poorer outcomes ...

TT‑P34 is designed to improve both mitochondrial and lysosomal function, targeting a pathway implicated in multiple ...

Clinical trials are becoming increasingly complex. In a 2023 survey, 70% of investigative site staff said conducting studies ...

There is currently no cure for PBC, with treatment aiming to manage symptoms, improve quality of life and slow disease ...

Clinical research is entering a new era: advances in methodological approaches, the growing integration of real-world ...

Cell Therapies has manufactured and released the first clinical dose for the KOALA trial, marking the start of a ...

Lucid Group has announced that Eric Muller has joined the agency as Chief Executive Officer. He succeeds CEO and original DiD ...

Diana F Clarke, Assistant Professor of Paediatrics at Boston University School of Medicine and Lead Investigator of the ...

Pace has appointed Andrew Fenny as President of Pace Life Sciences to lead the division into its next phase of strategic ...

Johnson & Johnson has welcomed Final Draft Guidance from NICE recommending Imbruvica (ibrutinib) with R‑CHOP, alternating with R‑DHAP or R‑DHAOx, followed by ibrutinib monotherapy, for adults with ...

Hi, this project/product/partnership is going live next week – can you do some comms?’ ...

The introduction of oral GLP-1 medicines, alongside growing awareness of injectable treatments such as Wegovy and Mounjaro, ...